Showing Latest Articles
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
International Journal of Clinical Practice, 03/15/2010
Seck T et al. – In patients with type 2 diabetes, adding sitagliptin to metformin monotherapy improved glycaemic control over 2 years, similar to the glucose–lowering efficacy observed with adding glipizide, but with greater durability and generally better maintenance of beta–cell function. Sitagliptin was generally well tolerated with a lower risk of hypoglycaemia and weight loss compared with weight gain observed with glipizide.
